Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies

/in

Ryan S. Roark, Rumi Habib, Jason Gorman, Hui Li, Andrew Jesse Connell, Mattia Bonsignori, Yicheng Guo, Michael P. Hogarty, Adam S. Olia, Kirsten J. Sowers, Baoshan Zhang, Frederic Bibollet-Ruche, Tatsiana Bylund, Sean Callaghan, John W. Carey, Gabriele Cerutti, Darcy R. Harris, Wanting He, Emily Lewis, Tracy Liu, Rosemarie D. Mason, Yujie Qiao, Younghoon Park, Juliette M. Rando, Ajay Singh, Jeremy J. Wolff, Q. Paula Lei, Mark K. Louder, Raiees Andrabi, Nicole A. Doria-Rose, Kevin O. Saunders, Michael S. Seaman, Barton F. Haynes, Daniel W. Kulp, John R. Mascola, Mario Roederer, Theodore C. Pierson, Zizhang Sheng, Beatrice H. Hahn, George M. Shaw, Peter D. Kwong, Lawrence Shapiro; Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies. J Exp Med 6 October 2025; 222 (10): e20250638. doi: https://doi.org/10.1084/jem.20250638

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial

/in

Parks KR, Moodie Z, Allen MA, Yen C, Furch BD, MacPhee KJ, Ozorowski G, Heptinstall J, Hahn WO, Zheng Z, Lu H, Grant S, Domin E, Duff MO, Seese A, Marini-Macouzet C, Ballweber-Fleming L, Lee WH, Cottrell CA, Liguori A, Georgeson E, Alavi N, Kubitz M, Phelps N, Seaton KE, Cohen KW, Anderson MA, Mondal K, Laufer DS, Kublin JG, Ward AB, Hyrien O, De Rosa SC, Himansu S, Leav B, Reuter C, Tomaras GD, Montefiori D, Walsh SR, Frank I, Sobieszczyk ME, Goepfert PA, Stephenson KE, Baden LR, Van Tieu H, Keefer MC, Clark J, Riddler SA, Schief WR, McElrath MJ. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Science Translational Medicine. 2025 Jul 30;17(809):eady6831. doi: 10.1126/scitranslmed.ady6831.

High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)

/in

Riddler SA, Moodie Z, Clark J, Yen C, Allen M, Furch BD, Lu H, Grant S, Mondal K, Anderson M, Maenza J, Lemos MP, Woodward Davis AS, Walsh SR, Sobieszczyk ME, Frank I, Goepfert P, Stephenson KE, Baden LR, Tieu HV, Keefer MC, McElrath MJ, Kublin JG, Corey L. High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302). Annals to Internal Medicine. 2025 Jul;178(7):963-974. doi: 10.7326/ANNALS-24-02701.

Functional Reprogramming of Peripheral Eosinophils in Lentivirus-Infected Rhesus Macaques

/in

Jones R, Afifi A, Reeves RK, Manickam C. Functional Reprogramming of Peripheral Eosinophils in Lentivirus-Infected Rhesus Macaques. AIDS Research and Human Retroviruses. 2025 Aug;41(8):411-413. doi: 10.1089/aid.2024.0105. Epub 2025 Jun 10.

Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma

/in

Liu SX, Wu TW, Luo DH, Zhang LL, Zhou L, Luo YL, Du WT, Huang TT, Jiang S, Zhang Z, Han P, Zeng MS, Zhong Q. Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell Reports Medicine. 2025 Jul 15;6(7):102200. doi: 10.1016/j.xcrm.2025.102200. Epub 2025 Jun 20.

Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques

/in

Jacob-Dolan C, Hope D, Liu J, Waller-Pulido A, Verrette B, Cabrera-Barragan DN, Nangle SJ, Wang Q, Blanc R, Fisher J, Lasrado N, Wang L, Cook A, Pessiant L, Lewis M, Andersen H, Hopps M, Scully IL, Allen PS, McNamara RP, Anderson AS, Barouch DH. Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques. Sci Transl Med. 2025 Jul 9;17(806):eadu7646. doi: 10.1126/scitranslmed.adu7646. Epub 2025 Jul 9.

HIV-1 nuclear import is selective and depends on both capsid elasticity and nuclear pore adaptability

/in

Hou Z, Shen Y, Fronik S, Shen J, Shi J, Xu J, Chen L, Hardenbrook N, Engelman AN, Aiken C, Zhang P. HIV-1 nuclear import is selective and depends on both capsid elasticity and nuclear pore adaptability. Nature Microbiology. 2025 Aug;10(8):1868-1885. doi: 10.1038/s41564-025-02054-z. Epub 2025 Jul 7.

A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV

/in

Sajadi, M. M., Abbasi, A., Tehrani, Z. R., Siska, C., Clark, R., Chi, W., Seaman, M. S., Mielke, D., Wagh, K., Liu, Q., Jumpa, T., Ketchem, R. R., Nguyen, D. N., Tolbert, W. D., Pierce, B. G., Atkinson, B., Deming, D., Sprague, M., Asakawa, A., Ferrer, D., … DeVico, A. (2025). A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV. Structure (London, England : 1993), 33(7), 1150–1164.e8. https://doi.org/10.1016/j.str.2025.04.016

Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques

/in

Morris DJ, Gorman J, Zhou T, Lora J, Connell AJ, Li H, Liu W, Roark RS, Campion MS, Carey JW, Habib R, Li Y, Martella CL, Park Y, Singh A, Sowers KJ, Teng IT, Wang S, Chohan N, Ding W, Lauer C, Lewis E, Mason RD, Rando JM, Peyton L, Schramm CA, Wagh K, Korber B, Seaman MS, Douek DC, Haynes BF, Kulp DW, Roederer M, Hahn BH, Kwong PD, Shaw GM. Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques. Cell Reports. 2025 Jun 24;44(6):115848. doi: 10.1016/j.celrep.2025.115848. Epub 2025 Jun 13.

Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: A systematic review and meta-analysis

/in

Chapman A, Barouch DH, Lip GYH, Pliakas T, Polverino E, Sourij H, Abduljawad S. Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: A systematic review and meta-analysis. International Journal of Infectious Diseases. 2025 Sep;158:107958. doi: 10.1016/j.ijid.2025.107958. Epub 2025 Jun 24.